Dexrazoxane reduces antithrombin activity: a case series.

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Dexrazoxane is used to prevent anthracycline-induced cardiotoxicity and treat extravasation.
• Thrombosis is not a common adverse effect but has been suggested as a potential risk.
• Anthracycline extravasation is a serious complication during chemotherapy.

Purpose of the Study:

• To investigate the potential association between dexrazoxane administration and decreased antithrombin activity.
• To explore the link between reduced antithrombin activity and thrombosis development.
• To raise awareness among clinicians regarding potential dexrazoxane-related adverse effects.

Main Methods:

• Case series presentation of three patients (four episodes) who received dexrazoxane.
• Monitoring of antithrombin activity levels following dexrazoxane administration.
• Review of previous reports on dexrazoxane and thrombosis.

Main Results:

• All three patients showed decreased antithrombin activity after dexrazoxane administration.
• Antithrombin activity reduction occurred a median of 4 days post-injection and recovered later.
• One patient developed deep-vein thrombosis, with no other apparent cause than dexrazoxane.

Conclusions:

• Dexrazoxane may be associated with a decline in antithrombin activity.
• This decrease in antithrombin activity could potentially contribute to thrombosis.
• Clinicians should monitor antithrombin levels and watch for thrombosis in patients on dexrazoxane.